Stay updated on FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab + Tremelimumab Clinical Trial
Sign up to get notified when there's something new on the FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab + Tremelimumab Clinical Trial page.

Latest updates to the FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab + Tremelimumab Clinical Trial page
- Check5 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check12 days agoChange DetectedA sitewide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” across NIH content.SummaryDifference1%

- Check19 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check26 days agoChange DetectedThe footer revision marker changes from v3.7.0 to v3.7.1 while the study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check40 days agoChange DetectedThe page now displays a 403 Forbidden error page with a simple header and navigation. This indicates restricted access to the study record rather than substantive content changes.SummaryDifference18%

- Check68 days agoChange DetectedAdded a note about the 2018 U.S. NIH Grant/Contract and updated the revision to v3.6.6, with the previous revision v3.6.5 removed.SummaryDifference0.1%

Stay in the know with updates to FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab + Tremelimumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab + Tremelimumab Clinical Trial page.